Adrenalitis and anasarca in idiopathic multicentric Castleman's disease.
作者信息
Chen Luke Y C, Skinnider Brian F, Wilson Don, Fajgenbaum David C
机构信息
Division of Haematology, University of British Columbia, Vancouver, BC, Canada; Centre for Health Scholarship, University of British Columbia, Vancouver, BC, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
出版信息
Lancet. 2021 May 8;397(10286):1749. doi: 10.1016/S0140-6736(21)00674-7.
Abstract
摘要
相似文献
1
Adrenalitis and anasarca in idiopathic multicentric Castleman's disease.
Lancet. 2021 May 8;397(10286):1749. doi: 10.1016/S0140-6736(21)00674-7.
2
Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.
CEN Case Rep. 2019 Nov;8(4):239-245. doi: 10.1007/s13730-019-00400-9. Epub 2019 May 10.
3
A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A.
Mod Rheumatol. 2019 Jan;29(1):198-202. doi: 10.1080/14397595.2016.1206243. Epub 2016 Jul 14.
4
Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report.
J Clin Exp Hematop. 2013;53(1):95-9. doi: 10.3960/jslrt.53.95.
5
TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.
Mod Rheumatol. 2018 May;28(3):564-569. doi: 10.3109/14397595.2015.1120389. Epub 2016 Feb 17.
6
Oral Baricitinib Restores Hair Loss in Alopecia Areata.
JAMA. 2022 Jun 28;327(24):2386. doi: 10.1001/jama.2022.10378.
7
[Castleman disease].
Ann Pathol. 2023 Jan;43(1):13-24. doi: 10.1016/j.annpat.2022.07.013. Epub 2022 Sep 30.
8
Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome.
Intern Med. 2016;55(2):185-90. doi: 10.2169/internalmedicine.55.4710. Epub 2016 Jan 15.
9
Delayed diagnosis of TAFRO syndrome: A case report.
Medicine (Baltimore). 2024 Aug 2;103(31):e39148. doi: 10.1097/MD.0000000000039148.
10
Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
Clin Exp Dermatol. 2021 Oct;46(7):1330-1332. doi: 10.1111/ced.14712. Epub 2021 Jun 4.
引用本文的文献
1
[Not Available].
CMAJ. 2025 Feb 9;197(5):E137-E141. doi: 10.1503/cmaj.240947-f.
2
TAFRO subtype of idiopathic multicentric Castleman disease in a 22-year-old man.
CMAJ. 2024 Nov 3;196(37):E1262-E1265. doi: 10.1503/cmaj.240947.
3
Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.
Eur J Haematol. 2024 Dec;113(6):833-841. doi: 10.1111/ejh.14295. Epub 2024 Aug 29.
4
Unexpected diagnosis of rare mesenteric Castleman disease: A case report and literature review.
Rare Tumors. 2024 Aug 4;16:20363613241257822. doi: 10.1177/20363613241257822. eCollection 2024.
5
Radiological Imaging Findings of Adrenal Abnormalities in TAFRO Syndrome: A Systematic Review.
Biomedicines. 2024 Apr 10;12(4):837. doi: 10.3390/biomedicines12040837.
6
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Blood Adv. 2023 Nov 14;7(21):6652-6664. doi: 10.1182/bloodadvances.2023010745.
7
Alveolar Hemorrhage in Idiopathic Multicentric Castleman's Disease.
Am J Respir Crit Care Med. 2023 Sep 1;208(5):613-615. doi: 10.1164/rccm.202204-0780IM.
8
Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.
Front Med (Lausanne). 2023 Jan 9;9:1037032. doi: 10.3389/fmed.2022.1037032. eCollection 2022.
9
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
Nat Commun. 2022 Nov 24;13(1):7236. doi: 10.1038/s41467-022-34873-7.
10
How we manage idiopathic multicentric Castleman disease.
Clin Adv Hematol Oncol. 2022 Sep;20(9):564-571.
Zotero 插件